{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T15:05:58Z","timestamp":1791385558887,"version":"4.3.3"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,10,19]],"date-time":"2015-10-19T00:00:00Z","timestamp":1445212800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s12885-015-1754-3","type":"journal-article","created":{"date-parts":[[2015,10,19]],"date-time":"2015-10-19T13:29:55Z","timestamp":1445261395000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Relapsing pneumonitis due to two distinct inhibitors of the MAPK\/ERK pathway: report of a case"],"prefix":"10.1186","volume":"15","author":[{"given":"Violaine","family":"Giraud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Longvert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sol\u00e8ne","family":"Houlle-Crepin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Danel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Labrune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Camus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Saiag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Chinet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,10,19]]},"reference":[{"issue":"26","key":"1754_CR1","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","volume":"364","author":"PB Chapman","year":"2011","unstructured":"Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507\u201316.","journal-title":"N Engl J Med"},{"issue":"28","key":"1754_CR2","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","volume":"380","author":"A Hauschild","year":"2012","unstructured":"Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012;380(28):358\u201365.","journal-title":"Lancet"},{"issue":"2","key":"1754_CR3","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1056\/NEJMoa1203421","volume":"367","author":"KT Flaherty","year":"2012","unstructured":"Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, et al. Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma. N Engl J Med. 2012;367(2):107\u201314.","journal-title":"N Engl J Med"},{"issue":"1","key":"1754_CR4","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1378\/chest.11-2479","volume":"142","author":"Y Lacasse","year":"2012","unstructured":"Lacasse Y, Girard M, Cormier Y. Recent advances in hypersensitivity pneumonitis. Chest. 2012;142(1):208\u201317.","journal-title":"Chest"},{"issue":"3","key":"1754_CR5","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1111\/crj.12071","volume":"8","author":"JF Xu","year":"2014","unstructured":"Xu JF, Shen L, Zhang Y, Zhang P, Qu JM, Li HP. Lung biopsy proved hypersensitivity pneumonitis without known offending antigen: characteristics and follow up. Clin Respir J. 2014;8(3):297\u2013304.","journal-title":"Clin Respir J"},{"issue":"1","key":"1754_CR6","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/S0272-5231(03)00138-2","volume":"25","author":"DB Flieder","year":"2004","unstructured":"Flieder DB, Travis WD. Pathologic characteristics of drug induced lung disease. Cli Chest Med. 2004;25(1):37\u201345.","journal-title":"Cli Chest Med"},{"issue":"4","key":"1754_CR7","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1055\/s-2003-42379","volume":"24","author":"J Myers","year":"2003","unstructured":"Myers J, Limper A, Swensen S. Drug-Induced lung disease: a pragmatic classification incorporating HRCT appearance. Sem Respir Crit Care Med. 2003;24(4):445\u201354.","journal-title":"Sem Respir Crit Care Med"},{"key":"1754_CR8","unstructured":"www.pneumotox.com . v2.0. Producer: Ph Camus 2013. Accessed July 12, 2014."},{"key":"1754_CR9","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1053\/crad.2001.0792","volume":"57","author":"J Cleverley","year":"2002","unstructured":"Cleverley J, Screaton N, Hiorns M, Flint J, Muller N. Drug-induced lung disese: high \u2013resolution CT and histologic findings. Clin Radiol. 2002;57:292\u20139.","journal-title":"Clin Radiol"},{"issue":"11","key":"1754_CR10","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1159\/000355643","volume":"36","author":"L Schmitt","year":"2013","unstructured":"Schmitt L, Schumann T, L\u00f6ser C, Dippel E. Vemurafenib-induced pulmonary injury. Onkologie. 2013;36(11):685\u20136.","journal-title":"Onkologie"},{"issue":"5","key":"1754_CR11","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1007\/s00280-011-1737-2","volume":"68","author":"JH Min","year":"2011","unstructured":"Min JH, Lee HY, Lim H, Ahn MJ, Park K, Chung MP, et al. Drug-induced interstitial lung disease in tyrosine kinase inhibitor therapy for non small cell lung cancer: a review on current insight. Cancer Chemother Pharmacol. 2011;68(5):1099\u2013109.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"18","key":"1754_CR12","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1056\/NEJMoa1210093","volume":"367","author":"KT Flaherty","year":"2012","unstructured":"Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012;367(18):1694\u2013703.","journal-title":"N Engl J Med"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-015-1754-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-015-1754-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-015-1754-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2016,10,6]],"date-time":"2016-10-06T21:53:17Z","timestamp":1475790797000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-015-1754-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,19]]},"references-count":12,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["1754"],"URL":"https:\/\/doi.org\/10.1186\/s12885-015-1754-3","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,19]]},"article-number":"732"}}